Table 1.
Gene | Overall summary of variants (n) | ||||
---|---|---|---|---|---|
ABCB4 | ABCB11 | ATP8B1 | NR1H4 | TJP2 | |
NSV | 68 | 77 | 50 | 22 | 83 |
After inclusion criteria | |||||
Total | 41 | 48 | 31 | 9 | 37 |
Pathogenicity | |||||
LP | 22 | 25 | 3 | 0 | 0 |
VUS | 13 | 18 | 23 | 8 | 35 |
Benign | 6 | 4 | 5 | 1 | 2 |
Phenotypes | |||||
ICP | 5 | 5 | 1 | 2 | 3 |
GD | 7 | 10 | 6 | 8 | |
Other | 1 (cholangiocarcinoma) | 1 (cirrhosis), 1 (cirrhosis with secondary malignant neoplasm of liver and bile duct, and gallstone disease) |
Inclusion criteria (< 5% MAF), NSV and at least any of the following: 1. Include all variants with a phenotype 2. Include all variants known in the literature 3. Include all variants with no GnomAD allele frequency but ELGH allele frequency 4. Include all variants with in silico prediction of 7.
GD, gallstone disease, ICP intrahepatic cholestasis of pregnancy, LP likely pathogenic, MAF minor allele frequency, NSV non-synonymous variants, VUS variant of unknown significance.